Aditxt to Acquire 50% Stake in Global Response Aid for Avigan Production

Aditxt has signed an asset purchase agreement with Cellvera to acquire 50% ownership of Global Response Aid (GRA) with rights to manufacture and market broad-spectrum antiviral drug Avigan. The consideration for the transaction is $24.5m, comprised of the forgiveness of Aditxt's $14.5m loan to Cellvera and $10m in cash, and future royalties for seven years. Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals. The closing of the transaction remains subject to a number of conditions, including regulatory approvals for the transfer of shares.